Navigation Links
NIDA Avant-Garde-Medications Development Award winners announced
Date:9/20/2011

Scientists proposing to develop vaccines against methamphetamine and nicotine have been selected to receive NIDA's second Avant-Garde Awards for Innovative Medication Development Research. The two scientists, Dr. Thomas Kosten, of Baylor College of Medicine, Houston, and Dr. Peter Burkhard, of the University of Connecticut, Storrs, will each receive $500,000 per year for five years to support their research, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

"Through this funding opportunity, NIDA once again strengthens its commitment toward developing safe and efficacious medications to treat addiction," said NIDA Director Nora D. Volkow, M.D. "This program expressly seeks to promote research projects that are ready for clinical translation and can accelerate the development of new medications."

Awardees are listed below:

Awardee: Thomas Kosten, Ph.D., Baylor College of Medicine
Project: Human methamphetamine vaccine

Dr. Kosten's group will accelerate the development of a methamphetamine vaccine, which is expected to undergo initial clinical trials within the next five years. At present there is no FDA-approved medication for methamphetamine addiction, so a vaccine could have substantial impact on the treatment of methamphetamine addiction.

Awardee: Peter Burkhard, Ph.D., University of Connecticut
Project: A peptide nanoparticle nicotine vaccine

Dr. Burkhard's lab plans to develop and test a novel type of vaccine that induces a strong immune response against nicotine without the need of chemical enhancers, which could result in a less expensive vaccine with fewer side effects. This nicotine vaccine will be administered intranasally, which will be more convenient and less painful than an injection. The new vaccine is expected to enter initial clinical trials within the next five years.

"Not only do these grantees have a strong background in vaccine research, but they also have clear plans for initiating clinical trials within an accelerated period of time," said Dr. Volkow. "They clearly represent the goal of the Avant-Garde program to support investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on the treatment of drug abuse."


'/>"/>

Contact: NIDA Press Team
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Related medicine news :

1. Transformative NIH grant will support development of tissue regeneration therapeutics
2. New strategy likely to speed drug development for rare cancers
3. Prenatal exposure to phthalates linked to decreased mental and motor development
4. Memory Development Incomplete Until Adulthood: Study
5. Researchers developing new test to measure risk for birth defects and neuro-developmental disorders
6. Sweet insight: Discovery could speed drug development
7. AMRI receives NIH contract award for development of pre-clinical drug candidates
8. NIH Blueprint empowers drug development for nervous system disorders
9. Penn researchers describe key molecule that keeps immune cell development on track
10. Sharing Bed With Toddler Wont Harm Development: Study
11. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: